These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 29385852)
1. Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors. Kramer B; Singh R; Wischusen J; Dent R; Rush A; Middlemiss S; Ching YW; Alexander IE; McCowage G Hum Gene Ther; 2018 Aug; 29(8):874-885. PubMed ID: 29385852 [TBL] [Abstract][Full Text] [Related]
2. In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model. Gori JL; Beard BC; Ironside C; Karponi G; Kiem HP Cancer Gene Ther; 2012 Aug; 19(8):523-9. PubMed ID: 22627392 [TBL] [Abstract][Full Text] [Related]
10. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652 [TBL] [Abstract][Full Text] [Related]
11. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647 [TBL] [Abstract][Full Text] [Related]
12. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. Larochelle A; Choi U; Shou Y; Naumann N; Loktionova NA; Clevenger JR; Krouse A; Metzger M; Donahue RE; Kang E; Stewart C; Persons D; Malech HL; Dunbar CE; Sorrentino BP J Clin Invest; 2009 Jul; 119(7):1952-63. PubMed ID: 19509470 [TBL] [Abstract][Full Text] [Related]
13. Clonal inventory screens uncover monoclonality following serial transplantation of MGMT P140K-transduced stem cells and dose-intense chemotherapy. Giordano FA; Sorg UR; Appelt JU; Lachmann N; Bleier S; Roeder I; Kleff V; Flasshove M; Zeller WJ; Allgayer H; von Kalle C; Fruehauf S; Moritz T; Laufs S Hum Gene Ther; 2011 Jun; 22(6):697-710. PubMed ID: 21319998 [TBL] [Abstract][Full Text] [Related]
14. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477 [TBL] [Abstract][Full Text] [Related]
15. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186 [TBL] [Abstract][Full Text] [Related]
16. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells. Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778 [TBL] [Abstract][Full Text] [Related]
17. Co-expression of MGMT(P140K) and alpha-L-iduronidase in primary hepatocytes from mucopolysaccharidosis type I mice enables efficient selection with metabolic correction. Wang D; Worsham DN; Pan D J Gene Med; 2008 Mar; 10(3):249-59. PubMed ID: 18076130 [TBL] [Abstract][Full Text] [Related]
18. Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection. Milsom MD; Williams DA DNA Repair (Amst); 2007 Aug; 6(8):1210-21. PubMed ID: 17482893 [TBL] [Abstract][Full Text] [Related]
19. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine. Woolford LB; Southgate TD; Margison GP; Milsom MD; Fairbairn LJ J Gene Med; 2006 Jan; 8(1):29-34. PubMed ID: 16075413 [TBL] [Abstract][Full Text] [Related]
20. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W; Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]